MGC Pharmaceuticals Ltd.

Date of AGM and Closing Date for Director Nominations

9 October 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company) advises that in accordance with ASX Listing Rule 3.13.1, the Company's Annual General Meeting is planned to be held on Thursday, 30 November 2023.

The closing date for receipt of nominations for persons wishing to be considered for election as a director is, 31 October 2023. Any nominations must be received at the Company's registered office no later than 5:00pm (AWST) on 24 October 2023.

-Ends-

Authorised for release by the Managing Director, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma